Abstract
The wide-ranging, multisystemic manifestations of sarcoidosis can make diagnosis and management difficult. Corticosteroid treatment is effective, but the optimal time to start, the dose, and the duration of treatment are controversial. We are just beginning to understand the genetic basis of sarcoidosis.
MeSH terms
-
Adrenal Cortex Hormones / therapeutic use
-
Antibodies, Monoclonal / therapeutic use
-
Biopsy
-
Clinical Trials, Phase II as Topic
-
Disease Susceptibility / etiology
-
Granuloma, Respiratory Tract / epidemiology
-
Granuloma, Respiratory Tract / pathology
-
Heart Diseases / diagnosis
-
Heart Diseases / epidemiology
-
Humans
-
Infliximab
-
Lung Diseases / diagnosis
-
Lung Diseases / epidemiology
-
Palliative Care
-
Prevalence
-
Prognosis
-
Pulmonary Fibrosis / prevention & control
-
Racial Groups
-
Sarcoidosis, Pulmonary / diagnosis
-
Sarcoidosis, Pulmonary / epidemiology
-
Sarcoidosis, Pulmonary / etiology*
-
Sarcoidosis, Pulmonary / therapy*
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Substances
-
Adrenal Cortex Hormones
-
Antibodies, Monoclonal
-
Tumor Necrosis Factor-alpha
-
Infliximab